Eloxx Pharmaceuticals, Inc. quarterly report, Q1 FY2012

Filing identity and reporting period

Important source mismatch: The supplied filing is Senesco Technologies, Inc.’s Form 10-Q, not an Eloxx Pharmaceuticals, Inc. filing. It covers the three months ended September 30, 2011, which the filing describes as its fiscal first quarter; the metadata’s “2011 Q1” does not match the filing period.

Senesco was a development-stage biotechnology company pursuing human therapeutic applications of its Factor 5A technology and licensing agricultural applications. The interim financial statements are unaudited.

Financial results and liquidity

There was no revenue, so a revenue-based margin is not meaningful. Research and development expense was $634,186, down 56.8%; general and administrative expense was $645,959, down 3.4%. The filing attributes much of the R&D decline to lower preclinical and toxicology spending on SNS01-T compared with the prior-year quarter.

Cash and cash equivalents were $2.842 million at September 30, 2011, down from $3.610 million at June 30, 2011. Working capital was $867,210. Investing activities used $128,839, primarily for patent costs; financing provided $451,097 net from common-stock sales under the ATM program.

Current liabilities were $3.799 million, including a $2.199 million line-of-credit balance. The credit facility allows up to $3.0 million subject to restrictions and suitable collateral; the stated interest rate at quarter-end was 3.75% plus 2.0%. Total liabilities were $4.339 million. The company reported $242,250 in dividends payable on outstanding preferred stock. No revenue or profit margins were reported.

Changes versus the prior comparable period

• Net loss declined by $976,493, or 48.4%, mainly due to lower operating expenses and other non-operating items.
• Operating cash use fell by about $515,000 year over year, while ending cash was $3.448 million below the prior-year quarter-end balance of $6.291 million.
• A $271,703 noncash gain from the reduction in warrant-liability fair value benefited current-quarter results; the corresponding prior-year gain was $319,476.
• During the quarter, Senesco sold 1,730,211 common shares through its ATM facility for $481,368 gross and $451,097 net proceeds. The preferred-stock conversion price reset from $0.30 to $0.27, adding 1.8 million potential conversion shares and a $778,000 deemed dividend.

Outlook, commentary, and risks

Management estimated that existing cash would fund operations through March 2012. It said ATM issuance, use of available line-of-credit capacity, and cost deferrals could extend funding through at least June 30, 2012. The company expected to need additional capital and warned that financing might not be available on acceptable terms, or at all. Without funding, it could reduce or stop development, license programs, seek strategic transactions, sell the company, cease operations, or declare bankruptcy.

The SNS01-T Phase 1b/2a multiple-myeloma study was open and treating patients. The planned dose-escalation study was intended primarily to assess safety and tolerability; tumor response would also be evaluated. The candidate had FDA orphan-drug status and an open IND. Management cited preclinical findings, including potential combination activity with approved myeloma drugs, but these are not clinical efficacy results.

Key risks include continued losses and no established product revenue; clinical, regulatory, manufacturing, and commercialization uncertainty; reliance on external research partners and commercial licensees; possible dilution from equity, preferred-stock conversions, options, and warrants; and NYSE Amex listing noncompliance. The company said it did not meet the exchange’s $6 million minimum net-worth requirement and planned to submit a compliance plan. It reported no legal proceedings and no off-balance-sheet arrangements.

Most important facts for investors to verify

• Confirm issuer and period: this source is Senesco Technologies’ quarter ended September 30, 2011, not an Eloxx filing.
• Verify the cash runway assumptions, available ATM capacity, and actual borrowing availability under the line of credit.
• Review subsequent financing, dilution, preferred-stock dividend and conversion terms, and warrant liabilities.
• Check the clinical study’s enrollment, safety findings, and regulatory status; the filing provides no patient outcome data.
• Confirm the outcome of the NYSE Amex compliance plan and any effect on listing or access to capital.